Spencer E Brightman
Overview
Explore the profile of Spencer E Brightman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soni D, Borriello F, Scott D, Feru F, DeLeon M, Brightman S, et al.
Sci Adv
. 2024 Jul;
10(27):eadg3747.
PMID: 38959314
Vaccination can help prevent infection and can also be used to treat cancer, allergy, and potentially even drug overdose. Adjuvants enhance vaccine responses, but currently, the path to their advancement...
2.
Miller A, Kosaloglu-Yalcin Z, Westernberg L, Montero L, Bahmanof M, Frentzen A, et al.
Sci Transl Med
. 2024 Feb;
16(736):eabj9905.
PMID: 38416845
The clinical impact of tumor-specific neoantigens as both immunotherapeutic targets and biomarkers has been impeded by the lack of efficient methods for their identification and validation from routine samples. We...
3.
Dolina J, Lee J, Brightman S, McArdle S, Hall S, Thota R, et al.
J Clin Invest
. 2023 Sep;
133(17).
PMID: 37655661
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition...
4.
Brightman S, Becker A, Thota R, Naradikian M, Chihab L, Soria Zavala K, et al.
Nat Immunol
. 2023 Jul;
24(8):1391.
PMID: 37464051
No abstract available.
5.
Brightman S, Becker A, Thota R, Naradikian M, Chihab L, Soria Zavala K, et al.
Nat Immunol
. 2023 Jul;
24(8):1345-1357.
PMID: 37400675
CD4 T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8 T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8 T...
6.
Dolina J, Lee J, Brightman S, McArdle S, Hall S, Thota R, et al.
bioRxiv
. 2023 May;
PMID: 37205330
Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition...
7.
Brightman S, Naradikian M, Thota R, Becker A, Montero L, Bahmanof M, et al.
JCI Insight
. 2022 Dec;
8(2).
PMID: 36512410
CD4+ T cells play a critical role in antitumor immunity via recognition of peptide antigens presented on MHC class II (MHC-II). Although some solid cancers can be induced to express...
8.
Dowling D, Barman S, Smith A, Borriello F, Chaney D, Brightman S, et al.
Sci Rep
. 2022 Oct;
12(1):16860.
PMID: 36258023
Infection is the most common cause of mortality early in life, yet the broad potential of immunization is not fully realized in this vulnerable population. Most vaccines are administered during...
9.
Brightman S, Naradikian M, Miller A, Schoenberger S
J Leukoc Biol
. 2020 Mar;
107(4):625-633.
PMID: 32170883
The goal of precision immunotherapy is to direct a patient's T cell response against the immunogenic mutations expressed on their tumors. Most immunotherapy approaches to-date have focused on MHC class...
10.
Queenan A, Dowling D, Cheng W, Fae K, Fernandez J, Flynn P, et al.
Vaccine
. 2018 Nov;
37(1):80-89.
PMID: 30478007
Current acellular-pertussis (aP) vaccines appear inadequate for long-term pertussis control because of short-lived efficacy and the increasing prevalence of pertactin-negative isolates which may negatively impact vaccine efficacy. In this study,...